Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking
Background:
Although advance has been made in understanding the pathogenesis of mature T-cell neoplasms, the initiation and progression of angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), remain poorly understood. A subset of AITL/PTCL-NOS patients develop concomitant hematologic neoplasms (CHN), and a biomarker to predict this risk is lacking.
Methods:
We generated and analyzed the mutation profiles through 537-gene targeted sequencing of the primary tumors and matched bone marrow/peripheral blood samples in 25 patients with AITL and two with PTCL-NOS.
Results:
Clonal hematopoiesis (CH)-associated genomic alterations, found in 70.4% of the AITL/PTCL-NOS patients, were shared among CH and T-cell lymphoma, as well as concomitant myeloid neoplasms or diffuse large B-cell lymphoma (DLBCL) that developed before or after AITL. Aberrant AID/APOBEC activity-associated and tobacco smoking-associated mutational signatures were respectively enriched in the early CH-associated mutations and late non-CH-associated mutations during AITL/PTCL-NOS development. Moreover, analysis showed that the presence of CH harboring ≥2 pathogenic TET2 variants with ≥15% of allele burden conferred higher risk for CHN (p=0.0006, hazard ratio = 14.01, positive predictive value = 88.9%, negative predictive value = 92.1%).
Conclusions:
We provided genetic evidence that AITL/PTCL-NOS, CH, and CHN can frequently arise from common mutated hematopoietic precursor clones. Our data also suggests smoking exposure as a potential risk factor for AITL/PTCL-NOS progression. These findings provide insights into the cell origin and etiology of AITL and PTCL-NOS and provide a novel stratification biomarker for CHN risk in AITL patients.
Funding:
R01 grant (CA194547) from the National Cancer Institute to WT.
Top-30
Journals
|
1
2
3
|
|
|
Frontiers in Oncology
3 publications, 10.34%
|
|
|
Current Oncology Reports
2 publications, 6.9%
|
|
|
Hemato
2 publications, 6.9%
|
|
|
Die Pathologie
2 publications, 6.9%
|
|
|
Signal Transduction and Targeted Therapy
1 publication, 3.45%
|
|
|
Molecular Cancer
1 publication, 3.45%
|
|
|
Frontiers in Immunology
1 publication, 3.45%
|
|
|
Blood Reviews
1 publication, 3.45%
|
|
|
International Journal of Hematology
1 publication, 3.45%
|
|
|
European Journal of Haematology
1 publication, 3.45%
|
|
|
American Journal of Clinical Pathology
1 publication, 3.45%
|
|
|
British Journal of Haematology
1 publication, 3.45%
|
|
|
Cold Spring Harbor molecular case studies
1 publication, 3.45%
|
|
|
Modern Pathology
1 publication, 3.45%
|
|
|
New England Journal of Medicine
1 publication, 3.45%
|
|
|
Human Pathology
1 publication, 3.45%
|
|
|
Blood
1 publication, 3.45%
|
|
|
British Journal of Dermatology
1 publication, 3.45%
|
|
|
Trends in Immunology
1 publication, 3.45%
|
|
|
Clinical and Experimental Medicine
1 publication, 3.45%
|
|
|
Proceedings of the Japan Academy Series B: Physical and Biological Sciences
1 publication, 3.45%
|
|
|
Blood Neoplasia
1 publication, 3.45%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
7
8
|
|
|
Springer Nature
8 publications, 27.59%
|
|
|
Elsevier
5 publications, 17.24%
|
|
|
Frontiers Media S.A.
4 publications, 13.79%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 10.34%
|
|
|
MDPI
2 publications, 6.9%
|
|
|
Wiley
2 publications, 6.9%
|
|
|
Oxford University Press
2 publications, 6.9%
|
|
|
Massachusetts Medical Society
1 publication, 3.45%
|
|
|
American Society of Hematology
1 publication, 3.45%
|
|
|
Japan Academy
1 publication, 3.45%
|
|
|
1
2
3
4
5
6
7
8
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.